A conserved dendritic-cell regulatory program limits antitumour immunity

• Published in: Nature (London) Vol. 580; no. 7802; pp. 257 - 262
• Main Authors: Maier, Barbara, Leader, Andrew M., Chen, Steven T., Tung, Navpreet, Chang, Christie, LeBerichel, Jessica, Chudnovskiy, Aleksey, Maskey, Shrisha, Walker, Laura, Finnigan, John P., Kirkling, Margaret E., Reizis, Boris, Ghosh, Sourav, D’Amore, Natalie Roy, Bhardwaj, Nina, Rothlin, Carla V., Wolf, Andrea, Flores, Raja, Marron, Thomas, Rahman, Adeeb H., Kenigsberg, Ephraim, Brown, Brian D., Merad, Miriam
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2020; Nature Publishing Group
• Subjects: 13/1; 13/31; 14/19; 38/91; 631/250/251; 631/250/580; 64/60; Analysis; Animals; Antigens; Antigens, Neoplasm - immunology; Antimitotic agents; Antineoplastic agents; Apoptosis; Axl protein; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Cancer; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - therapy; CC chemokine receptors; CCR7 protein; CD200 antigen; CD40 antigen; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Cell adhesion & migration; Control; Dendritic cells; Dendritic Cells - drug effects; Dendritic Cells - immunology; Dendritic Cells - metabolism; Dendritic Cells - pathology; Dendritic structure; Effector cells; Gene sequencing; Genes; Humanities and Social Sciences; Humans; Immune checkpoint; Immunity; Immunity (Disease); Immunoregulation; Immunotherapy; Interferon; Interferon-gamma - immunology; Interleukin 1; Interleukin-12 - immunology; Interleukin-4 - antagonists & inhibitors; Interleukin-4 - immunology; Interleukin-4 - metabolism; Kinases; Ligands; Lung cancer; Lung Neoplasms - immunology; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Lungs; Lymphatic system; Lymphocytes; Lymphocytes T; Male; Metastasis; Mice; multidisciplinary; Protein-tyrosine kinase receptors; Proteins; Ribonucleic acid; RNA; Science; Science (multidisciplinary); Tumor Burden - drug effects; Tumor Burden - immunology; Tumor necrosis factor-TNF; Tumors; Tyrosine; United States
• ISSN: 0028-0836; 1476-4687; 1476-4687
• DOI: 10.1038/s41586-020-2134-y

Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control the response to checkpoint blockade in preclinical models and are associated with better overall survival in patients w...